Nanotechnologies for the Detection of Glycopeptides

Nanotechnologies for the Detection of Glycopeptides

Many low concentrations of glycoproteins/glycopeptides in serum or tissue extracts are biomarkers with high clinical sensitivity and specificity, and these biomolecules could provide important information for disease pathogenesis exploration, disease marker discovery, and protein-based drug development. However, it is still a challenge for glycoproteomics to selective isolation and enrichment of glycoproteins/glycopeptides from complex biological samples due to their low concentrations. Currently,  nanotechnologies have been widely used for the detection of glycopeptides due to their high sensitivity and specificity.

Nanomaterials possess larger surface areas than bulk materials because of their smaller size. In the context of rapid and sensitive detection, this feature provides additional activation sites for glycopeptide enrichment and unique optical properties. The most promising property of nanomaterials is the degree to which their shape, size, and morphology could be precisely controlled to enhance the electronic, optical, or magnetic capabilities typically required in certain applications. Several nanoplatforms are currently available at CD BioGlyco for the separation of glycopeptides in complex samples with higher sensitivity and specificity.

Overview of different nanomaterials  (outside the blue circle) used in combination with biomaterials/biomolecules  (inside the blue circle) for various applications (in yellow circle). Fig.1 Overview of different nanomaterials (outside the blue circle) used in combination with biomaterials/biomolecules (inside the blue circle) for various applications (in yellow circle). (Dosekova, 2017)

Our Services

Guarantees

  • Considerable savings and short experimental cycle time
  • High precision, sensitivity, and specificity
  • Convenient operation and good reproducibility
  • Optimization of experimental routes according to customers’ requirements

With a high level of research capability and professionally educated researchers, CD BioGlyco has developed a variety of nanotechnologies and successfully applied them to the detection of low-abundance endogenous glycoproteins/glycopeptides. If you have a demand in this field, please contact us for technical support and we will be delighted to provide you with the best service.

Reference

  1. Dosekova, E.; et al. Nanotechnology in glycomics: applications in diagnostics, therapy, imaging, and separation processes. Medicinal Research Reviews. 2017, 37(3): 514-626.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.
0